... evaluation) Clinical trials Recurrent Bladder Cancer Combination chemotherapy Immunotherapy Targeted therapy Surgery for new superficial or localized tumors Palliative therapy Clinical trials BCG = bacillus Calmette-Guérin; ...

... cancer immunotherapy Follow-up after targeted therapy or immunotherapy is important, as late adverse events may develop. The increased use of combination treatment may disclose new adverse events that have not yet been recognized. ...

... therapy before or after concurrent chemoradiation therapy . Consolidation ... schedules (under clinical evaluation). Radiosensitizers ( NCT02186847 ) (under ...

... syndrome, however, the result was not statistically significant. Additional studies have demonstrated similar survival outcomes ... that develop via the MSI pathway have more ...

... of outcomes, and variable time of assessment from treatment exposures. In ... neurological events across their lifetimes than siblings. No plateau has ...

... therapy and chemotherapy . Palliative chemotherapy and other ... metastatic cervical cancer whose tumors express programmed death-ligand 1 (PD-L1) (combined ...

... alternative drug doses and schedules Recurrent disease Chemotherapy ... advances, most patients with SCLC die of their tumor even with the best available therapy. Most of ...

... been given previously A second surgery , if the tumor was not completely ... Clinical trials evaluating additional radiation therapy using hyperfractionated ...

... often with adjuvant intravesical therapy to destroy residual tumor cells using chemotherapeutic agents (e.g., ... Fatigue Syndrome Pacific Northwest ...

... years are eligible for the trial. Patients with tumors that have molecular ... website . New agents under clinical evaluation in phase I and ...